PTJ
NPCE icon

Paul Tudor Jones’s Neuropace NPCE Stock Holding History

Paul Tudor Jones’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.75M Sell
109,874
-25,831
-19% -$416K ﹤0.01% 2037
2026
Q1 		$1.78M Sell
135,705
-57,641
-30% -$865K ﹤0.01% 1929
2025
Q4 		$2.99M Buy
193,346
+39,648
+26% +$530K 0.01% 1516
2025
Q3 		$1.58M Buy
153,698
+34,807
+29% +$328K ﹤0.01% 1959
2025
Q2 		$1.32M Buy
118,891
+70,881
+148% +$886K ﹤0.01% 1953
2025
Q1 		$590K Buy
+48,010
New +$601K ﹤0.01% 2178

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Paul Tudor Jones's NPCE Position: Q2 2026 in Review

Paul Tudor Jones reduced its Neuropace (NPCE) stake by 19% in Q2 2026, selling an estimated $416K and leaving 109,874 shares worth $1.75M. The position accounts for ﹤0.01% of the portfolio, ranked #2037.

Paul Tudor Jones first reported a position in NPCE in Q1 2025 and has held it in 6 quarters since. The position peaked at $2.99M in Q4 2025. 112 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • Paul Tudor Jones held 109,874 shares of Neuropace worth $1.75M as of Q2 2026.
  • Paul Tudor Jones sold 25,831 Neuropace shares in Q2 2026, an estimated $416K.
  • Neuropace made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #2037 holding.
  • Paul Tudor Jones first reported a position in Neuropace in Q1 2025 and has held it in 6 quarters since.
  • Paul Tudor Jones's Neuropace position peaked at $2.99M in Q4 2025.
  • 112 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.